Literature DB >> 7805197

Relevance of blockade of cardiac and circulatory angiotensin-converting enzyme for the prevention of volume overload-induced cardiac hypertrophy.

M Ruzicka1, F H Leenen.   

Abstract

BACKGROUND: Angiotensin-converting enzyme (ACE) inhibitors show major differences in their affinity for cardiac and other tissue ACEs, and their effects on tissue ACE range from minimal to nearly complete blockade. Angiotensin II taken up from the circulation or generated in the heart may mediate the cardiac hypertrophic response to increased cardiac load. Thus, differences between the ACE inhibitors regarding their effects on cardiac ACE may determine their effects on prevention or regression of cardiac hypertrophy. METHODS AND
RESULTS: In the present study, we assessed the effects of ACE inhibitors with low (enalapril) and high (quinapril) affinity for cardiac tissue ACE on prevention of volume overload-induced cardiac hypertrophy in relation to their hemodynamic effects. Both blockers were equipotent for circulatory ACE as assessed from the pressure response curve to angiotensin I. Both blockers partially (and similarly) prevented the increase in left ventricular end-diastolic pressure by aortocaval shunt. However, only quinapril prevented or attenuated the development of right ventricular hypertrophy and left ventricular hypertrophy and dilation.
CONCLUSIONS: The present findings further stress the involvement of the renin-angiotensin system as a trophic stimulus in the development of cardiac hypertrophy in this model. Moreover, the low affinity of enalapril for cardiac ACE appears to lead to continuous angiotensin II generation in the heart and can thus explain the failure of enalapril to attenuate hypertrophic response of the heart induced by shunt despite decreasing cardiac volume overload.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7805197     DOI: 10.1161/01.cir.91.1.16

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  7 in total

1.  Apoptosis, cell proliferation and modulation of cyclin-dependent kinase inhibitor p21(cip1) in vascular remodelling during vein arterialization in the rat.

Authors:  Thaiz Ferraz Borin; Ayumi Aurea Miyakawa; Leandro Cardoso; Luciano de Figueiredo Borges; Giovana Aparecida Gonçalves; Jose Eduardo Krieger
Journal:  Int J Exp Pathol       Date:  2009-06       Impact factor: 1.925

Review 2.  Should we aim at tissue renin-angiotensin systems?

Authors:  J F Smits; R C Passier; M J Daemen
Journal:  Pharm World Sci       Date:  1998-06

Review 3.  Formulary management of ACE inhibitors.

Authors:  K R Gerbrandt; K C Yedinak
Journal:  Pharmacoeconomics       Date:  1996-12       Impact factor: 4.981

Review 4.  The renin-angiotensin system and the heart: beyond 2000.

Authors:  T Morgan; H R Brunner
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

5.  Regulation of protein kinase C isozymes in volume overload cardiac hypertrophy.

Authors:  Martin U Braun; Paul LaRosée; Gregor Simonis; Mathias M Borst; Ruth H Strasser
Journal:  Mol Cell Biochem       Date:  2004-07       Impact factor: 3.396

6.  Weaving hypothesis of cardiomyocyte sarcomeres: discovery of periodic broadening and narrowing of intercalated disk during volume-load change.

Authors:  Makoto Yoshida; Eiketsu Sho; Hiroshi Nanjo; Masato Takahashi; Mikio Kobayashi; Kouiti Kawamura; Makiko Honma; Masayo Komatsu; Akihiro Sugita; Misa Yamauchi; Takahiro Hosoi; Yukinobu Ito; Hirotake Masuda
Journal:  Am J Pathol       Date:  2010-01-07       Impact factor: 4.307

Review 7.  Neurohormones, inflammatory mediators, and cardiovascular injury in the setting of heart failure.

Authors:  Liza Grosman-Rimon; Filio Billia; Evan Wright; Shemy Carasso; Gabby Elbaz-Greener; Erez Kachel; Vivek Rao; David Cherney
Journal:  Heart Fail Rev       Date:  2020-09       Impact factor: 4.214

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.